
A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

